{"id":16240,"date":"2022-05-15T18:16:44","date_gmt":"2022-05-15T16:16:44","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16240"},"modified":"2022-05-15T18:16:44","modified_gmt":"2022-05-15T16:16:44","slug":"sarclisa-isatuximab-en-association-permet-dobtenir-un-allongement-sans-precedent-la-survie-mediane-sans-progression-des-patients-atteints-dun-myelome-multiple-en-rechute-traites-par-un-inh","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/sarclisa-isatuximab-en-association-permet-dobtenir-un-allongement-sans-precedent-la-survie-mediane-sans-progression-des-patients-atteints-dun-myelome-multiple-en-rechute-traites-par-un-inh\/","title":{"rendered":"Sarclisa\u00ae (isatuximab) en association permet d&#8217;obtenir un allongement sans pr\u00e9c\u00e9dent la survie m\u00e9diane sans progression des patients atteints d&#8217;un my\u00e9lome multiple en rechute trait\u00e9s par un inhibiteur du prot\u00e9asome"},"content":{"rendered":"<p>Les derniers r\u00e9sultats de l&#8217;essai clinique IKEMA de phase III \u00e9valuant Sarclisa<sup>\u00ae<\/sup> (isatuximab) en association avec le carfilzomib et ladexam\u00e9thasone (Kd) montrent que cette association th\u00e9rapeutique a permis d&#8217;obtenir une survie m\u00e9diane sans progression de 35,7 mois (Hazard Ratio [HR] 0,58 ; intervalle de confiance [IC] \u00e0 95\u00a0% : 25,8 \u00e0 44,0\u00a0; n=179), comparativement \u00e0 19,2 mois chez les patients ayant re\u00e7u le traitement Kd seulement (IC \u00e0 95\u00a0%\u00a0: 15,8 \u00e0 25,1\u00a0; n=123), selon l&#8217;\u00e9valuation r\u00e9alis\u00e9e par un comit\u00e9 ind\u00e9pendant. Ces r\u00e9sultats, qui ont \u00e9t\u00e9 pr\u00e9sent\u00e9s au Congr\u00e8s mondial \u00ab <em>Controversies in Mutliple Myeloma<\/em> \u00bb, attestent de la plus longue survie m\u00e9diane sans progression jamais observ\u00e9e dans les \u00e9tudes consacr\u00e9es \u00e0 un traitement de fond de deuxi\u00e8me ligne du my\u00e9lome multiple (MM) en rechute par un inhibiteur du prot\u00e9asome. Ces donn\u00e9es seront \u00e9galement pr\u00e9sent\u00e9es au congr\u00e8s de la Soci\u00e9t\u00e9 europ\u00e9enne d&#8217;oncologie m\u00e9dicale le 19 mai prochain.<\/p>\n<p><em>\u00ab\u00a0Un allongement remarquable de la survie sans progression a \u00e9t\u00e9 observ\u00e9 dans tous les sous-groupes de patients pr\u00e9sentant un my\u00e9lome multiple en rechute trait\u00e9s par un inhibiteur du prot\u00e9asome en association avec d&#8217;autres m\u00e9dicaments, lorsque Sarclisa a \u00e9t\u00e9 ajout\u00e9 au<\/em> <em>carfilzomib<\/em> <em>et \u00e0 la<\/em> <em>dexam\u00e9thasone. Les rechutes sont fr\u00e9quentes<\/em> <em>chez les patients atteints d&#8217;un my\u00e9lome multiple, d&#8217;o\u00f9 la n\u00e9cessit\u00e9 de leur administrer des traitements de deuxi\u00e8me ligne diff\u00e9renci\u00e9s qui allongent leur survie sans progression. Cette analyse actualis\u00e9e montre que Sarclisa a bel et bien le potentiel de devenir un nouveau traitement de r\u00e9f\u00e9rence pour les patients pr\u00e9sentant un my\u00e9lome multiple en rechute. \u00bb<\/em><\/p>\n<p><em><b>Pr Philippe Moreau<\/b><\/em><\/p>\n<p>Chef du service d&#8217;h\u00e9matologie, CHU de Nantes, France.<\/p>\n<p style=\"text-align: right;\"><em>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de Sanofi.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Les derniers r\u00e9sultats de l&#8217;essai clinique IKEMA de phase III \u00e9valuant Sarclisa\u00ae (isatuximab) en association avec le carfilzomib et ladexam\u00e9thasone (Kd) montrent que cette association th\u00e9rapeutique a permis d&#8217;obtenir une [&hellip;]<\/p>","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-16240","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16240"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16240"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}